

Advertising | Exhibitions | Events | Hospitality

June 10, 2021

BSE Limited25th Floor, P J Towers,
Dalal Street, Fort,
Mumbai- 400 001
Scrip Code: 531637

Dear Sirs,

Sub.: Submission of Audited Financial Results for the quarter / year ended March 31, 2021 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to above, we hereby submit / inform that:

- The Board of Directors ("the Board") at its meeting held today, commenced at 12:00 noon and concluded at 02:40 pm, has approved the Audited Financial Statements (Standalone and Consolidated) for the year ended March 31, 2021 and the Audited Financial Results (Standalone and Consolidated) for the quarter / year ended March 31, 2021, as recommended by the Audit Committee.
- 2. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:
 - (i) Audited Financial Results (Standalone and Consolidated) for the quarter / year ended March 31, 2021;
 - (ii) Auditors' Reports with unmodified opinions on the aforesaid Audited Financial Results (Standalone and Consolidated); and
 - (iii) Declaration by CFO on unmodified opinion on Auditors Report' issued by the Statutory Auditors, under Regulation 33(3)(d) of the Listing Regulations.

Kindly take the above on your record.

Thanking You,

Yours Faithfully,

For Praveg Communications (India) Limited

(Formerly known as Sword and Shield Pharma Limited)

Mukesh Chaudhary Company Secretary & Compliance Officer

Encl. : As Above



PRAVEG COMMUNICATIONS (INDIA) LIMITED



June 10, 2021

BSE Limited 25th Floor, P J Towers, Dalal Street, Fort, Mumbai- 400 001 Scrip Code: 531637

Dear Sirs,

Sub: Declaration pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

I, Viral Doshi, Chief Financial Officer of Praveg Communications (India) Limited ('the Company') hereby declare that, the Statutory Auditors of the Company, M/s. B.K. Patel & Co., Chartered Accountants (Firm Registration No. 112647W) have issued an Audit Report with unmodified opinion on Audited Financial Results of the Company (Standalone & Consolidated) for the quarter and year ended on March 31, 2021.

This Declaration is given in compliance to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended by the SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2016, vide notification No. SEBI/LAD-NRO/GN/2016-17/001 dated May 25, 2016 and Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016.

Kindly take this declaration on your records.

Thanking You,

Yours Faithfully,

For Praveg Communications (India) Limited

(Formerly known as Sword and Shield Pharma Limited)

Viral Doshi

Chief Financial Officer





B. K. PATEL & CO Chartered Accountants

401-404, VRAJ Valencia, B/h. Mahindra Show Room, Nr. Sola Overbridge, S.G. Highway, Sola, AHMEDABAD—380 060, Gujarat.

Phone: 079-2970 0974/75 • Email: bkpatelandco@gmail.com

Independent Auditor's Report on the Quarterly and Year to Date Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors,
Praveg Communications (India) Limited
(Formerly Sword and Shield Pharma Limited)
Ahmedabad

Report on the audit of the Consolidated Financial Results

Opinion

We have audited the accompanying statement of quarterly and year to date consolidated financial results of Praveg Communications (India) Limited (Formerly Sword and Shield Pharma Limited) ("Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), its associate and joint ventures for the quarter and year ended March 31, 2021 ("Statement"), attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us and considering the reports of the other auditors on separate audited financial statements and on other financial information of the subsidiaries and joint venture, the Statement;

- i. includes the results of Subsidiaries i.e. Praveg Communications Aus Pty Limited and Praveg Communications USA Inc, Praveg Tourism Private Limited and a Joint Venture Sardar Sarovar Tourism Opportunities. However Praveg Tourism Private Limited ceased to be subsidiary during the year.
- ii. is presented in accordance with the requirements of the Listing Regulations in this regard; and

iii. gives a true and fair view in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of the consolidated net profit and other comprehensive income and other financial information of the Group for the quarter and year ended March 31, 2021.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs), as specified under Section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Consolidated Financial Results" section of our report. We are independent of the Group, its associate and joint ventures in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.



Emphasis of Matter

We draw attention to Note No.8 to the consolidated financial results which explain the uncertainties and the management's assessment of the financial impact due to the lockdown and other restrictions related to the COVID-19 pandemic situation, for which a definitive assessment of the impact in the subsequent period is highly dependent upon circumstances as they evolve. Our opinion is not modified in respect of the matter.

We draw attention to Note No.6 of the accompanying financial results regarding accounting of the merger as per the scheme from the appointed date being 1st April, 2016 as approved by the National Company Law Tribunal (NCLT), Ahmedabad Bench, though the Scheme has become operationally effective on March 1, 2020 the restatement of comparatives for the previous year (or period) of both amalgamating and amalgamated companies including all of their subsidiaries and joint ventures have been regrouped and merged in the consolidated financial statements.

Management's Responsibilities for the Consolidated Financial Results

The Statement has been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of the Statement that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group including its associate and joint ventures in accordance with the applicable accounting standards prescribed under section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group and of its associate and joint ventures are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and its associate and joint ventures and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group and of its associate and joint ventures are responsible for assessing the ability of the Group and of its associate and joint ventures to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its associate and joint ventures are also responsible for overseeing the financial reporting process of the Group and of its associate and joint ventures.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:



- · Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- · Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- · Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associate and joint ventures to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associate and joint ventures to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.
- · Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group and its associate and joint ventures of which we are the independent auditors and whose financial information we have audited, to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of the financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the Statement of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities Exchange Board of India under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

Other Matter

- The accompanying Statement includes the audited / certified financial statements and other financial information, in respect of:
- (a) 2 subsidiaries and 1 joint venture, whose financial statements include total assets of Rs.13.34 lakhs as at March 31, 2021, total revenues of Rs.4.48 lakhs, total net profit after tax of Rs.4.24 lakhs for the year ended on March 31, 2021, as considered in the Statement out of which the audit of 2 subsidiaries and 1 joint venture have been carried by their respective independent auditors.



- (b) The independent auditor's report / certified special purpose financial statements of these entities have been furnished to us by the Management and our opinion on the Statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, joint venture is based on the reports of such auditors and the procedures performed by us as stated in paragraph above.
- (c) In our opinion and according to the information and explanations given to us by the Management, these financial statements and other financial information are not material to the Group.
- (d) Our opinion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the attested documents of other auditors and financial information certified by the Management.
- 2. The Statement includes the results for the quarter ended March 31, 2021 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2021 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to limited review by us, as required under the Listing Regulations.

PATEL & FRN: 112647W AHMEDABAD

For, B. K. PATEL & CO Chartered Accountants Firm Regn No. 112647W

Partner Membership No.039919

UDIN: 21039919AAAADH6464

Ahmedabad 10-6-2021

(FORMERLY KNOWN AS SWORD AND SHIELD PHARMA LIMITED)

Regd Office: 214, Athena Avenue, Behind Jaguar Showromm, S.G. Highway, Gota, Ahmedabad GJ 382481

CIN: L24231GJ1995PLC024809

Website :- www.praveg.com

Email Id:- cs@praveg.com

Audited Consolidated Statement of Financial Results for the Quarter and Year ended March 31, 2021

(Rs. In Lakh except per share data)

Denticulare	Quarter Ended		Year Ended		
Particulars	31-03-2021	31-12-2020	31-03-2020	31-03-2021	31-03-2020
	Ref Note No.1	Unaudited	Ref Note No.1	Audited	Audited
1 INCOME					
i Revenue From Operations	2,196.36	1,797.71	2,293.40	4,531.52	5,956.15
ii Other Income	7.59	4.35	13.00	33.37	35.57
Total Income	2,203.95	1,802.06	2,306.40	4,564.89	5,991.72
2 Expenses					
i Event & Site Expenses	1,193.35	905.78	1,262.70	2,256.34	4,467.29
ii Employee Benefit Expenses	105.03	101.14	155.22	377.38	432.01
iii Finance Costs	18.05	6.18	15.31	33.47	54.32
iii Depreciation and Amortisation Expense	61.58	34.34	28.50	164.10	97.39
iv Other Expenses	143.62	73.77	211.78	307.17	418.36
Total Expenses	1,521.63	1,121.21	1,673.51	3,138.46	5,469.37
Profit / (Loss) before loss of share of Joint venture, exceptional items and Tax	682.32	680.85	632.89	1,426.43	522.35
4 Share of Profit /(loss) from joint venture	0.01	0.00	0.32	0.01	0.32
5 Profit / (Loss) before exceptional items and Tax	682.33	680.85	633.21	1,426.44	522.67
6 Exceptional items	0.00	0.00	0.00	0.00	0.00
7 Profit / (Loss) before Tax	682.33	680.85	633.21	1,426.44	522.67
8 Tax Expense	163.28	171.44	153.37	352.38	142.65
i Current Tax	186.10	171.44	160.02	375.20	156.93
ii Deferred Tax	(22.82)	0.00	(6.65)	(22.82)	(14.28)
9 Profit (Loss) for the period from continuing operations	519.05	509.41	479.84	1,074.06	380.02
i Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00
ii Tax expenses of discontinued operations	0.00	0.00	0.00	0.00	0.00
10 Profit for the Period	519.05	509.41	479.84	1,074.06	380.02
11 Other Comprehensive Income	3.99	0.00	0.00	3.99	0.00
12 Total comprehensive income for the Period	523.04	509.41	479.84	1,078.05	380.02
13 Paid-up equity share capital [Face value, Rs.10 per share]	1,848.41	1,848.41	1,848.41	1,848.41	1,848.41
14 Earnings per equity share [Basic + Diluted] *	2.83	2.76	2.60	5.83	2.06

^{*} Quarterly EPS are not Annualised

(FORMERLY KNOWN AS SWORD AND SHIELD PHARMA LIMITED)

Regd Office: 214, Athena Avenue, Behind Jaguar Showromm, S.G. Highway, Gota, Ahmedabad GJ 382481

CIN: L24231GJ1995PLC024809

Website :- www.praveg.com

Email Id:- cs@praveg.com

Audited Consolidated Balance Sheet as at 31-March-2021

(Rs. In Lakh except per share data)

n !	As at	Lakh except per share data) As at
Particulars	31-Mar-2021	31-Mar-2020
I <u>Assets</u>		
1 Non-current Assets		
(a) Property, Plant and Equipment	218.53	308.41
(b) Right-of-use assets	318.17	0.00
(c) Other Intangible Assets	3.72	0.30
(d) Financial Assets		
(i) Non Current Investment	9.74	9.72
(iv) Other Non-Current Financial Assets	33.08	0.00
(e) Deferred Tax Assets (Net)	45.70	22.88
(f) Other Non Current Assets	0.00	7.65
Total Non-current Assets	628.94	348.96
2 Current Assets		
(a) Inventories	428.52	244.28
(b) Financial Assets	120.32	211.20
(i) Trade Receivables	581.26	1,410.27
(ii) Cash and Cash Equivalents	914.49	277.14
(iii) Other Bank Balance	4.94	30.16
(iv) Current Loans	13.11	0.06
(v) Other Financial Assets	13.95	56.57
(c) Current Tax Assets (Net)	9.35	0.00
(d) Other Current Assets	103.61	109.26
Total Current Assets	2,069.23	2,127.74
Total Assets	2,698.17	2,476.70
1 Equity (a) Equity Share Capital (b) Other Equity (c) Non-Controlling interests Total Equity	1,848.41 57.33 0.00 1,905.74	1,848.41 (373.59 10.46 1,485.28
2 Liabilities		
2A Non-current Liabilities		
(a) Financial Liabilities		
(i) Non-current Borrowings	16.03	91.83
(ii) Lease Liabilities (b) Long Term Provisions	221.69 20.71	0.00 22.00
Total Non-current Liabilities	258.43	113.83
PB Current Liabilities		
(a) Financial Liabilities		
(i) Current Borrowings	72.72	97.42
(ii) Lease Liabilities (iii) Trade Payables	68.78 276.81	0.00 514.39
(b) Current tax liabilities (net)	0.00	44.21
(c) Short Term Provisions	83.14	44.12
(d) Other Current Liabilities	32.55	177.46
Total Current Liabilities	534.00	877.59
		004.45
Total Liabilities		991.42

(FORMERLY KNOWN AS SWORD AND SHIELD PHARMA LIMITED)

Regd Office: 214, Athena Avenue, Behind Jaguar Showromm, S.G. Highway, Gota, Ahmedabad GJ 382481

CIN: L24231GJ1995PLC024809

Website :- www.praveg.com

Email Id:- cs@praveg.com

Audited Consolidated Statement of Cash Flow for the year ended 31-3-2021

			Amount in Rs. in Lakhs
	Particulars	For the Year ended	For the Year ended
Λ	CASH FLOW FROM OPERATING ACTIVITIES	31-3-2021	31-3-2020
Α	CASH FLOW FROM OPERATING ACTIVITIES		
	Net Profit before Tax	1,431.77	522.67
	Adjustments for:		
	Depreciation and Amortisation Expense	164.10	97.36
	Finance costs recognised in profit or loss	33.47	54.32
	Interest income	(8.73)	(14.33)
	Loss on disposal of property, plant and equipment	2.24	0.01
	Gain on disposal of a subsidiary	0.00	0.00
	Sundry Balances Written off	0.00	(26.11)
	Reversal of Sundry Balances Written off	(19.48)	0.00
	Impairment loss recognised on trade receivables	21.62	0.00
	Foreign Exchange Gain	0.00	(21.21)
	Net foreign exchange Loss	2.20	0.00
	Operating profits before working capital changes	1,627.19	612.71
	Changes in working capital		
	(Increase)/decrease in inventories	(184.24)	(48.52)
	(Increase)/decrease in Trade Receivables	826.87	(78.24)
	(Increase)/decrease in other assets	37.27	22.81
	Increase/(decrease) in Trade payables	(238.14)	105.58
	Decrease in other liabilities and provisions	(118.64)	96.55
		323.12	98.18
	Cash generated from operations	1,950.31	710.89
	Taxes (paid)	(430.10)	(122.24)
	Net Cash generated from operating activities	1,520.21	588.65
В	Cash flow from Investing activities		
	Daymonts for property plant and aguinment	(40.20)	(125.05)
	Payments for property, plant and equipment	(49.28)	(135.95)
	Payments for intangible assets Investment in Joint Venture	(3.71)	0.00
		(0.02)	(18.42)
	Bank deposit or margin money withdrawn / (deposited)	(0.21)	73.37
	Loan received back / (given) from / to others	(13.05)	0.00
	Net cash inflow on disposal of subsidiary Interest received	8.73	0.00
		8.73	19.15
	Net cash generated from / (used in) Investing activities	(48.81)	(61.85)
С	Cash flow from Financing activities		
	Proceeds from borrowings	(100.49)	(207.84)
	Dividends paid to owners of the Company	(646.94)	(42.86)
	Repayment of Lease	(53.15)	0.00
	Finance cost paid	(33.47)	(54.32)
	Tax on buy back of shares	0.00	(6.86)
	Net Cash (used in) / generated from Financing activities	(834.05)	(311.88)
	Net increase in Cash & Cash equivalents (A+B+C)	637.35	214.92
	Cash and Cash equivalents received from acquisition Cash and Cash equivalents at the beginning of the year	0.00 277.14	0.00 62.22
	Cash and Cash equivalents at the end of the year	914.49	
	Cash and Cash equivalents at the end of the year	914.49	277.14

(FORMERLY KNOWN AS SWORD AND SHIELD PHARMA LIMITED)

Regd Office: 214, Athena Avenue, Behind Jaguar Showromm, S.G. Highway, Gota, Ahmedabad GJ 382481 CIN: L24231GJ1995PLC024809 Website:- www.praveg.com Email Id:- cs@praveg.com

Notes forming part of consolidated financial results;

- 1 The Audit Committee has reviewed the above results and the Board of Directors has approved the above results at their respective meetings held on June 10, 2021.
- 2 The above consolidated financial results of the Group are in compliance with Indian Accounting Standards (Ind AS) specified under section 133 of The Companies Act, 2013, generally accepted accounting principles in India read with SEBI circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 and have been subjected to audit by the Statutory Auditors.
- 3 The figures for the corresponding previous period have been regrouped/reclassified wherever necessary, to make them comparable for the users of the financial statements.
- 4 Consolidated figures for the quarter ended on March 31 are the balancing figures between the audited figures in respect of the year ended March 31, 2021 and the published unaudited year-to-date figures up to the third quarter of the current financial year and comparative previous year. The consolidated figures in respect of the year / quarter ended March 31, 2021 were approved by the Board of Directors and have not been subjected to limited review by the Statutory Auditors.
- 5 In view of the amalgamation of Praveg Communications Limited with Praveg Communications (India) Limited (Formerly known as Sword and Shield Pharma Limited), the financial results given for all periods includes financials of Transferor Company incorporated with that of Resulting Company as a better comparative for the readers of the financial results.
- 6 During the last Quarter of FY 2019-20, Hon'ble National Company Law Tribunal, Ahmedabad Bench (NCLT) has approved the Scheme of Amalgamation (the Scheme) with an appointed date of April 1, 2016 and the Scheme became effective on January 24, 2020 on filing the certified copies of the orders sanctioning the scheme with the Registrar of Companies (RoC), whereas it has become operationally effective from March 1, 2020.

Pursuant to the Scheme:

Praveg Communications Limited (hereinafter referred to as "PCL") has been amalgamated with Sword and Shield Pharma Limited. (hereinafter referred to as "SSPL"). As per clause no. 7.3 (Page no. 13 of 21) of Scheme, name of the transferee Company has been changed from Sword and Shield Pharma Limited to Praveg Communications (India) Limited (hereinafter referred to as "PCIL").

<u>Pursuant to Scheme of Amalgamation, following subsidiary/Joint Venture of Praveg Communications Limited became</u> subsidiary/Joint Venture of Praveg Communications (India) Limited (hereinafter referred to as "PCIL").

- 1 List of Subsidiaries
 - a Praveg Tourism Private Limited (During the FY 2020-21, ceased to be subsidiary)
 - b Praveg Communications Aus Pty Limited
 - c Praveg Communications USA Inc
- 2 List of Joint Venture
 - a Sardar Sarovar Tourism Opportunities.
- 7 The Scheme has been accounted for as per the accounting treatment approved by the NCLT read with accounting standards prescribed under section 133 of the Companies Act, 2013. The amalgamation of PCL with PCIL (formerly SSPL) has resulted into debit balance of capital reserve of Rs.1315.57 lakhs.

(FORMERLY KNOWN AS SWORD AND SHIELD PHARMA LIMITED)

Regd Office: 214, Athena Avenue, Behind Jaguar Showromm, S.G. Highway, Gota, Ahmedabad GJ 382481 CIN: L24231GJ1995PLC024809 Website:- www.praveg.com Email Id:- cs@praveg.com

Notes forming part of consolidated financial results;

8 The Outbreak of Coronavirus (COVID-19) pandemic globally and in India is causing significant disturbance and slowdown of economic activities. Measures taken to contain the spread of the virus, including travel bans, quarantines, social distancing, and closures of non-essential services have triggered significant disruptions to businesses worldwide, resulting in an economic slowdown. Holding of events and exhibitions being undertaken by the Company had been temporarily suspended during nationwide lockdown. Business operations have been resumed in a phased manner in line with directives from the authorities.

The Company has considered internal and external sources of information up to the date of approval of these consolidated financial results, in assessing the recoverability of its trade receivables, inventories, investments in and loans given to subsidiaries, liquidity, financial position and operations of the Company and based on the management's assessment, there is no material impact on the consolidated financial results of the Company.

Considering the uncertainties involved in estimating the impact of this force majure pandemic situation, the future impact of this pandemic may be different from those estimated as on the date of approval of these consolidated financial results.

9 Accounting of Errors in calculating depreciation rate based on useful life specified in Schedule II of Companies Act 2013 as per Ind AS 08.

As per Ind AS 08 on Accounting Policies, Changes in Accounting Estimates and Errors, Depreciation and amortization increased by 0.67 Lakhs and corresponding WDV for the Year ended on March 31, 2020 is reduced by 0.67 Lakhs, Deferred Tax Expenses for the Year ended on March 31, 2020 reduced by 14.20 Lakhs. As a result net profit after tax increased by 13.53 Lakhs.

The Company has also incressed its Current Tax Expenses for the FY 2019-20 by 1.05 lakhs, which was error while consolidating results of group. As a result cummulative net effect on Net Profit after tax is 12.48 Lakhs.

Opening Balance as on April 01, 2019 of WDV of Property, Plant and Equipment balance reduced by 15.92 Lakhs, Deferred Tax Assets reduced by 7.41 Lakhs and Retained Earnings reduced by 23.33 Lakhs.

- 10 Revenue from operations includes unbilled sale of service of Rs. 94.25 Lakhs.
- 11 On account of change in effective estimated useful life of building constructed on lease hold land due to change in lease period, in a result of it, depreciation of Rs.13.60 lakhs on building has been charged for this quarter under review.



B. K. PATEL & CO Chartered Accountants

401-404, VRAJ Valencia, B/h. Mahindra Show Room, Nr. Sola Overbridge, S.G. Highway, Sola, AHMEDABAD—380 060, Gujarat. Phone: 079-2970 0974/75 Email: bkpatelandco@gmail.com

Independent Auditor's Report on the Quarterly and Year to Date Audited Standalone Financial Resultsof the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and DisclosureRequirements) Regulations, 2015, as amended

To,
The Board of Directors,
Praveg Communications (India) Limited
(Formerly Sword & Shield Pharma Limited)
Ahmedabad

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying statement of quarterly and year to date standalone financial results of **Praveg Communications** (India) **Limited** (Formerly Sword and Shield Pharma Limited)(the "Company") for the quarter and year ended March 31, 2021("Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- is presented in accordance with the requirements of the Listing Regulations in this regard;
 and
- ii. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the quarter and year ended March 31, 2021.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter paragraph

- We draw attention to Note No.8to the standalone financial results which explain the
 uncertainties and the management's assessment of the financial impact due to the lockdown
 and other restrictions related to the COVID-19 pandemic situation, for which a definitive
 assessment of the impact in the subsequent period is highly dependent upon circumstances as
 they evolve. Our opinion is not modified in respect of the matter.
- 2. We draw attention to Note No. 6 to the accompanying financial results regarding accounting of the scheme from the appointed date being April 1, 2016 as approved by the National Company Law Tribunal (NCLT), Ahmedabad Bench, though the Scheme has become operationally effective from March 1, 2020, the restatement of comparatives for the previous year (or period) of both amalgamating and amalgamated companies.



Management's Responsibilities for the Standalone Financial Results

The Statement has been prepared on the basis of the standalone annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- · Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- · Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- · Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.



· Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the plannedscope and timing of the audit and significant audit findings, including any significant deficiencies ininternal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevantethical requirements regarding independence, and to communicate with them all relationships and othermatters that may reasonably be thought to bear on our independence, and where applicable, relatedsafeguards.

Other Matter

The Statement includes the results for the quarter ended March 31, 2021 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2021 and the published unaudited year-to-date figures upto the third quarter of the current financial year, which were subjected to limited review by us, as required under the Listing Regulations.

FRN: 112647W AHMEDABAD

For, B.K. PATEL & CO Chartered Accountants Firm Regn No. 112647W

K.D.Patel Partner Membership No.039919

UDIN: 21039919AAAADG3275

Ahmedabad 10-6-2021

(FORMERLY KNOWN AS SWORD AND SHIELD PHARMA LIMITED)

Regd Office: 214, Athena Avenue, Behind Jaguar Showromm, S.G. Highway, Gota, Ahmedabad GJ 382481

CIN: L24231GJ1995PLC024809

Website :- www.praveg.com

Email Id:- cs@praveg.com

Audited Statement of Standalone Financial Results for the Quarter and Year ended March 31, 2021

(Rs. In Lakh except per share data)

	(Rs. In Lakh except per s					
Particulars	Quarter Ended			Year Ended		
	31-03-2021	31-12-2020	31-03-2020	31-03-2021	31-03-2020	
	Ref Note No.1	Unaudited	Ref Note No.1	Audited	Audited	
1 INCOME						
i Revenue From Operations	2,196.39	1,797.71	2,293.40	4,527.05	5,956.80	
ii Other Income	7.59	4.35	13.00	42.60	30.46	
Total Income	2,203.98	1,802.06	2,306.40	4,569.65	5,987.26	
2 Expenses						
i Event & Site Expenses	1,193.35	905.78	1,262.70	2,256.34	4,467.29	
ii Employee Benefit Expenses	105.03	101.14	155.22	377.38	432.01	
iii Finance Costs	18.05	6.18	15.31	33.41	54.01	
iii Depreciation and Amortisation Expense	61.58	34.34	28.50	164.10	97.39	
iv Other Expenses	142.83	73.73	211.43	306.15	416.25	
Total Expenses	1,520.84	1,121.17	1,673.16	3,137.38	5,466.95	
3 Profit / (Loss) before loss of share of Joint venture, exceptional items and Tax	683.14	680.89	633.24	1,432.27	520.31	
4 Share of Profit /(loss) from joint venture	0.00	0.00	0.00	0.00	0.00	
5 Profit / (Loss) before exceptional items and Tax	683.14	680.89	633.24	1,432.27	520.31	
6 Exceptional items	0.00	0.00	0.00	0.00	0.00	
7 Profit / (Loss) before Tax	683.14	680.89	633.24	1,432.27	520.31	
8 Tax Expense	163.23	171.44	152.32	352.38	142.44	
i Current Tax	186.05	171.44	158.97	375.20	156.72	
ii Deferred Tax	(22.82)	0.00	(6.65)	(22.82)	(14.28)	
9 Profit (Loss) for the period from continuing operations	519.91	509.45	480.92	1,079.89	377.87	
i Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	
ii Tax expenses of discontinued operations	0.00	0.00	0.00	0.00	0.00	
10 Profit for the Period	519.91	509.45	480.92	1,079.89	377.87	
11 Other Comprehensive Income	3.99	0.00	0.00	3.99	0.00	
12 Total comprehensive income for the Period	523.90	509.45	480.92	1,083.88	377.87	
13 Paid-up equity share capital [Face value, Rs.10 per share]	1,848.41	1,848.41	1,848.41	1,848.41	1,848.41	
14 Earnings per equity share [Basic + Diluted] *	2.83	2.76	2.60	5.86	2.04	

^{*} Quarterly EPS are not Annualised

(FORMERLY KNOWN AS SWORD AND SHIELD PHARMA LIMITED)

Regd Office: 214, Athena Avenue, Behind Jaguar Showromm, S.G. Highway, Gota, Ahmedabad GJ 382481

CIN: L24231GJ1995PLC024809

Website :- www.praveg.com

Audited Standalone Balance Sheet as at March 31, 2021

Email Id:- cs@praveg.com

	Particulars	As at	As at
_		31-Mar-2021	31-Mar-2020
1	Assets		
1	Non-current Assets	242.52	200.44
	(a) Property, Plant and Equipment	218.53	308.41
	(b) Right-of-use assets	318.17	0.00
	(c) Other Intangible Assets	3.72	0.30
	(d) Financial Assets		
	(i) Non Current Investment	20.67	21.17
	(iv) Other Non-Current Financial Assets	33.08	0.00
	(e) Deferred Tax Assets (Net)	45.70	22.88
	(f) Other Non Current Assets	0.00	6.95
	Total Non-current Assets	639.87	359.71
2	Current Assets		
	(a) Inventories	428.52	244.28
	(b) Financial Assets	504.06	4 202 67
	(i) Trade Receivables	581.26	1,292.67
	(ii) Cash and Cash Equivalents (iii) Other Bank Balance	911.15 4.94	252.22 30.16
	(iv) Current Loans	15.34	124.04
	(v) Other Financial Assets	13.95	56.57
	(c) Current Tax Assets (Net)	9.35	0.00
	(d) Other Current Assets	103.61	109.18
	Total Current Assets	2,068.12	2,109.12
	Total Assets	2,707.99	2,468.83
	Equity and liabilities Equity		
_	(a) Equity Share Capital	1,848.41	1,848.41
	(b) Other Equity	67.43	(369.51)
	Total Equity	1,915.84	1,478.90
2	Liabilities	-,	-,
2A	Non-current Liabilities	27.70	
	(a) Financial Liabilities		
	(i) Non-current Borrowings	16.03	91.83
	(ii) Lease Liabilities	221.69	0.00
	(b) Long Term Provisions	20.71	22.00
	Total Non-current Liabilities	258.43	113.83
2B	Current Liabilities		
	(a) Financial Liabilities		
	(i) Current Borrowings	72.43	97.41
	(ii) Lease Liabilities	68.78	0.00
	(iii) Trade Payables	276.82	512.94
	(b) Current tax liabilities (net)	0.00	44.21
	(c) Short Term Provisions	83.14	44.12
	(d) Other Current Liabilities	32.55	177.42
	Total Current Liabilities	533.72	876.10
	Total Liabilities	792.15	989.93
	Total Equity and Liabilities	2,707.99	2,468.83

(FORMERLY KNOWN AS SWORD AND SHIELD PHARMA LIMITED)

Regd Office: 214, Athena Avenue, Behind Jaguar Showromm, S.G. Highway, Gota, Ahmedabad GJ 382481

CIN: L24231GJ1995PLC024809

Website :- www.praveg.com

Email Id:- cs@praveg.com

Audited Standalone Cash Flow Statement for the year ended on March 31, 2021

	Particulars	For the Year ended	Amount in Rs. in Lakhs For the Year ended
Δ	CASH FLOW FROM OPERATING ACTIVITIES	31-3-2021	31-3-2020
	Net Profit before Tax	1,437.60	520.31
	Adjustments for:	1,437.00	320.31
	Depreciation and Amortisation Expense	164.10	97.38
	Finance costs recognised in profit or loss	33.41	54.01
	Investment income recognised in profit or loss	1.00	0.00
	Interest income	(8.73)	
		0.00	(9.24) 0.01
	Loss on disposal of property, plant and equipment		
	Gain on disposal of a subsidiary	(8.23)	0.00
	Gain on disposal of interest in former associate	0.00	0.00
	Sundry Balances Written off	0.00	26.11
	Reversal of Sundry Balances Written off	(19.48)	0.00
	Impairment loss recognised on trade receivables	21.62	0.00
	Reversal of impairment loss on trade receivables	0.00	0.00
	Foreign Exchange Gain	0.00	(21.21)
	Net foreign exchange Loss	2.20	0.00
	Operating profits before working capital changes	1,623.49	667.37
	Changes in working capital		
	(Increase)/decrease in inventories	(184.24)	(48.52)
	Increase in trade and other receivables	709.27	(536.31)
	(Increase)/decrease in other assets	45.99	(15.50)
	Decrease in trade and other payables	(238.14)	209.06
	(Decrease)/increase in other liabilities and provisions	(107.14)	98.90
		225.74	(292.37)
1	Cash generated from operations	1,849.23	375.00
	Income taxes paid	(430.10)	(119.39)
	Net Cash generated from operating activities	1,419.13	255.61
В	Cash flow from Investing activities		
	Payments for property, plant and equipment	(47.04)	(135.97)
	Payments for intangible assets	(3.13)	0.00
	Bank deposit or margin money withdrawn / (deposited)	(0.91)	73.37
	Interest received (Finance Income)	8.73	14.07
	Dividends received from associates/subsidiary	(1.00)	0.00
	Loan Repayments by Others	108.70	441.97
	Net cash inflow on disposal of subsidiary	8.73	0.00
	Investment in Joint Venture	0.00	(18.09)
	Net cash generated from / (used in) Investing activities	74.08	375.35
С	Cash flow from Financing activities		
	Repayment of borrowings	(100.78)	(370.57)
	Dividends paid to owners of the Company	(646.94)	(42.86)
	Repayment of Lease	(53.15)	0.00
	Finance Cost	(33.41)	(54.01)
	Tax on buy back of shares	0.00	(6.85)
	Net Cash (used in) / generated from Financing activities	(834.28)	(474.29)
-	Net increase in Cash & Cash equivalents (A+B+C)	658.93	156.67
-	Cash and cash equivalents at the beginning of the year	252.22	95.55
	Effects of exchange rate changes on the balance of cash held in foreign currencies	0.00	0.00
	Eneces of exchange rate changes on the balance of cash held in foleigh currences	0.00	0.00

(FORMERLY KNOWN AS SWORD AND SHIELD PHARMA LIMITED)

Regd Office: 214, Athena Avenue, Behind Jaguar Showromm, S.G. Highway, Gota, Ahmedabad GJ 382481

CIN: L24231GJ1995PLC024809 Website:- www.praveg.com Email Id:- cs@praveg.com

Notes forming part of standalone financial results;

- 1 The Audit Committee has reviewed the above results and the Board of Directors has approved the above results at their respective meetings held on June 10, 2021.
- 2 The above standalone financial results of the company are in compliance with Indian Accounting Standards (Ind AS) specified under section 133 of The Companies Act, 2013, generally accepted accounting principles in India read with SEBI circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 and have been subjected to audit by the Statutory Auditors.
- 3 The figures for the corresponding previous period have been regrouped/reclassified wherever necessary, to make them comparable for the users of the financial statements.
- 4 Standalone figures for the quarter ended on March 31 are the balancing figures between the audited figures in respect of the year ended March 31, 2021 and the published unaudited year-to-date figures up to the third quarter of the current financial year and comparative previous year. The standalone figures in respect of the year / quarter ended March 31, 2021 were approved by the Board of Directors and have not been subjected to limited review by the Statutory Auditors.
- 5 In view of the amalgamation of Praveg Communications Limited with Praveg Communications (India) Limited (Formerly known as Sword and Shield Pharma Limited), the financial results given for all periods includes financials of Transferor Company incorporated with that of Resulting Company as a better comparative for the readers of the financial results.
- 6 During the last Quarter of FY 2019-20, Hon'ble National Company Law Tribunal, Ahmedabad Bench (NCLT) has approved the Scheme of Amalgamation (the Scheme) with an appointed date of April 1, 2016 and the Scheme became effective on January 24, 2020 on filing the certified copies of the orders sanctioning the scheme with the Registrar of Companies (RoC), whereas it has become operationally effective from March 1, 2020.

Pursuant to the Scheme:

Praveg Communications Limited (hereinafter referred to as "PCL") has been amalgamated with Sword and Shield Pharma Limited. (hereinafter referred to as "SSPL"). As per clause no. 7.3 (Page no. 13 of 21) of Scheme, name of the transferee Company has been changed from Sword and Shield Pharma Limited to Praveg Communications (India) Limited (hereinafter referred to as "PCIL").

<u>Pursuant to Scheme of Amalgamation, following subsidiaries/Joint Venture of Praveg Communications Limited became subsidiaries/Joint Venture of Praveg Communications (India) Limited (hereinafter referred to as "PCIL").</u>

- 1 List of Subsidiaries
 - a Praveg Tourism Private Limited (During the FY 2020-21, ceased to be subsidiary)
 - b Praveg Communications Aus Pty Limited
 - c Praveg Communications USA Inc
- 2 List of Joint Venture
 - a Sardar Sarovar Tourism Opportunities.
- 7 The Scheme has been accounted for as per the accounting treatment approved by the NCLT read with accounting standards prescribed under section 133 of the Companies Act, 2013. The amalgamation of PCL with PCIL (formerly SSPL) has resulted into debit balance of capital reserve of Rs.1315.57 lakhs.
- 8 The Outbreak of Coronavirus (COVID-19) pandemic globally and in India is causing significant disturbance and slowdown of economic activities. Measures taken to contain the spread of the virus, including travel bans, quarantines, social distancing, and closures of non-essential services have triggered significant disruptions to businesses worldwide, resulting in an economic slowdown. Holding of events and exhibitions being undertaken by the Company had been temporarily suspended during nationwide lockdown. Business operations have been resumed in a phased manner in line with directives from the authorities.

The Company has considered internal and external sources of information up to the date of approval of these standalone financial results, in assessing the recoverability of its trade receivables, inventories, investments in and loans given to subsidiaries, liquidity, financial position and operations of the Company and based on the management's assessment, there is no material impact on the standalone financial results of the Company.

(FORMERLY KNOWN AS SWORD AND SHIELD PHARMA LIMITED)

Regd Office: Shop No. First Floor, 101, Shanti Arcade, 132 Feet Ring Road, Naranpura Ahmedabad GJ 380013 Email Id:- cs@praveg.com

CIN: L24231GJ1995PLC024809 Website :- www.praveg.com

Notes forming part of standalone financial results;

Considering the uncertainties involved in estimating the impact of this force majure pandemic situation, the future impact of this pandemic may be different from those estimated as on the date of approval of these standalone financial results.

9 Accounting of Errors in calculating depreciation rate based on useful life specified in Schedule II of Companies Act 2013 as per Ind AS 08.

As per Ind AS 08 on Accounting Policies, Changes in Accounting Estimates and Errors, Depreciation and amortization increased by 0.67 Lakhs and corresponding WDV for the Year ended on March 31, 2020 is reduced by 0.67 Lakhs, Deferred Tax Expenses for the Year ended on March 31, 2020 reduced by 14.20 Lakhs. As a result net profit after tax increased by 13.53 Lakhs.

Opening Balance as on April 01, 2019 of WDV of Property, Plant and Equipment has been reduced by Rs.15.92 Lakhs, Deferred Tax Assets reduced by Rs.7.41 Lakhs and Retained Earnings reduced by Rs.23.33 Lakhs.

- 10 Revenue from operations includes unbilled sale of service of Rs.188.50 Lakhs.
- 11 On account of change in effective estimaed useful life of building constructed on lease hold land due to change in lease period, in a result of it, deprecition of Rs.13.75 lakhs on building has been charged for this quarter under review.

For, Praveg Communications (India) Limited

Vishnukumar Patel Chairman

Date: June 10, 2021 Place: Ahmedabad